The newly approved drug, which treats potentially fatal pulmonary arterial hypertension, is estimated to ring up as much as $7.5 billion in yearly sales.
Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep Covid cliff and investor pressure to spend their windfalls wisely.
Pharmaceutical companies that made billions from the pandemic over the past 2 years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their windfalls wisely.
Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their